Seletalisib

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameSeletalisib
Drug Alias Nameseletalisibum司来利塞seletalisib塞来利司UCB-5857
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphatidylinositol 3 kinase delta inhibitors
TargetsPhosphatidylinositol 3 kinase delta
Therapy Area/IndicationsImmunologic Deficiency SyndromesPsoriasisSjogren's Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySwedenItalyUnited Kingdom +[5] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesUcb
China Registration ClassN/A

Develop Information

Active CompaniesUcb
Inactive CompaniesUcb CelltechUcb Pharma
Active IndicationsImmunologic Deficiency Syndromes
Inactive IndicationsPsoriasisSjogren's Syndrome

Other Information

ATC CodeN/A
Related LinksN/A